Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Zerlasiran lowered lipoprotein(a) by more than 80% at 36 ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Comparing extremes of the spectrum, multivariable analyses generally showed significantly higher risks for patients with high ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Talk to your doctor about getting your lipoprotein(a) levels tested. Sandra Revill Tremulis was a healthy 39-year-old who taught fitness classes and had recently run a marathon when extreme fatigue ...